Pay in 4 interest-free payments of $7.16 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
Since the first GLP-1R agonist, exenatide, was approved for the treatment of T2DM in 2005, a variety of GLP-1R agonists such as liraglutide and dulaglutide have been approved
clinicians will favor the safest, lowest-effective option to maintain GLP-1 therapy adherence
Zepbound (tirzepatide) is fully approved by the FDA and widely available for both type 2 diabetes and weight loss
Human clinical trials resulted in 10.4% average weight loss over six months which is notable for an oral supplement and positions it as a meaningful, research-backed oral option for people seeking non-injectable approaches
Treatment with liraglutide injection 1.8 mg resulted in statistically significant reductions in HbA 1c and FPG relative to exenatide (Table 9)
For Q2, Eli Lilly reported a 38% year-over-year jump in revenue to $15.56 billion, attributed to volume growth from the weight loss drugs Zepbound and Mounjaro
US$ 25.67
.webp)
US$ 20.62
US$ 24.80
.webp?width=900&height=1201&name=Semaglutide%20Image%202_900x1200%20(without%20phone).webp)
US$ 24.07
US$ 26.58
US$ 25.34
US$ 28.81
US$ 25.37
US$ 28.16
